" an internal QUT probe that last year cleared the scientists of misconduct." " accused the researchers of exaggerating some results."
I don't find this comforting. The mud has already been flying out the window, and some of it sticks regardless of the outcome. I wonder if the retraction of the paper and the credibility factor has had a hand in the company not being able to find a Pharma partner at that time. I always wondered why, when this is supposed to be so wonderful, didn't anyone come up to bat. Certainly wasn't going to be Invitrogen.
I think this has a bit more to play out. Its a smear on the credibility of some people and institutions that does not get totally washed away, and Tissue Therapies is in this.
Research scientists are supposed to be very specific and accurate with data etc, so I don't think the "inadvertent" mistake in filling out the grant application washes with anyone.
And that name Boston comes up again. Sends a chill up my spine.
TIS Price at posting:
23.3¢ Sentiment: LT Buy Disclosure: Held
